GIVING LONG ACTING CABENUVA IN AN INFUSION CENTER (GLACIER) STUDY
Background
Cabotegravir and Rilpivirine Long Acting requires a paradigm shift in how HIV care is delivered. People living with HIV (PLHIV) will attend appointments for their injections once a month or once every 2-months as opposed to seeing their providers one to two times per year. Expanding where the treatment is administered has the potential to address workload capacity and may positively impact treatment engagement and retention for PLHIV. Infusion Centers may be an appealing option for some PLHIV and HIV Care providers as it may ease the burden of additional appointments, administrative work, and drug ordering in HIV specialty clinics and provide PLHIV greater flexibility in where they receive their injections.
Goals
This primary objective of this study is to evaluate the feasibility of CABENUVA administration at infusion centers from participants with HIV-1.
Design
Eligible and consenting participants will be followed for 8 months to evaluate and scale-up an implementation blueprint for administration of Cabotegravir and Rilpivirine Long Acting for HIV-1 treatment at Infusion Centers. Prior to the first participant first visit, an Expert Panel will meet to generate a blueprint to guide successful implementation. The blueprint will be optimized over the first 6 months and will be used as a foundation for the enrolment of the remaining participants. While the injections will take place at the Infusion center, these participants will receive Cabotegravir and Rilpivirine Long Acting via prescription from their HIV care provider and will continue to be monitored according to usual standard care at their physician’s discretion. Quantitative and qualitative data will be collected from patient participants, Infusion Center staff and HIV care providers throughout the study to understand feasibility and acceptability of using and Infusion Center to administer Cabotegravir and Rilpivirine Long Acting as well to examine the scale-up of the implementation blueprint across Infusion Centers in the study.
ViiV Study Lead and Contact
Cassidy Gutner, PhD, Senior Director of Global Implementation Research
Collaborators
Evidera
Setting
Infusion Centers in the United States
Location
U.S.A.
Duration
Nov 2021 – Jul 2024
Study ID
Collaboration Study – IMP 214747
Category
Long-Acting Prevention and Treatment
Study focus areas
Our implementation research projects have a global reach and focus on improving the HIV prevention and care continuum.
NP-GBL-HVX-WCNT-220049 October 2023
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
